NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory
23 Août 2022 - 1:30PM
NightHawk Biosciences (NYSE American:
NHWK), a fully-integrated biopharmaceutical company
focused on developing first-in-class therapies to modulate the
immune system, today announced the construction of an advanced
biosafety level 2 (BSL-2) laboratory, adding biodefense and
infectious disease capabilities to the Company’s research
facilities in Research Triangle Park, North Carolina.
Jeff Wolf, NightHawk’s CEO, commented, “Given
the unprecedented global biological threats facing our nation, both
natural and man-made, this new, state-of-the-art BSL-2 laboratory
will enable us to work with select attenuated agents such as
anthrax and botulinum toxins, tularemia, monkeypox and other
priority DOD agents and pathogens of global concern. The buildout
of this facility follows our acquisition of biodefense company
Elusys Therapeutics and represents the next stage in our efforts to
develop medical countermeasures to protect the population against
emerging biothreats.”
Matthew M. Seavey, PhD, Vice President of
Research of NightHawk commented, “This new BSL-2 facility is being
designed to accommodate research on high-priority infectious
agents. As such, we are implementing strict safety measures within
this facility, including enhanced safety monitoring, independent
powered air filtration units (PAPR), HEPA filtered unidirectional
HVAC units, and high security restricted access for secure entry,
all measures that are critical for the BSL-2 classification. In
addition, we have increased our vivarium footprint, allowing us to
execute and enhance data generation related to infectious disease
preclinical studies, in order to evaluate the efficacy,
immunogenicity, and safety of vaccines and therapeutics against
bacterial and viral pathogens.”
NightHawk Biosciences,
Inc.NightHawk Biosciences is a fully-integrated
biopharmaceutical company focused on the development of new drugs
from discovery through commercialization. The Company leverages its
integrated ecosystem of subsidiaries to accelerate the development
of novel therapies that arm the immune system, breaking through
barriers that prolong traditional drug development. This empowers
us to bring our ideas to life with efficient control, superior
quality, and uncharacteristic agility.
For more information on the Company and is
subsidiaries, please visit: www.nighthawkbio.com, and also
follow us on Twitter.
Forward Looking StatementThis
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions, and include statements such as the state-of-the-art
BSL-2 laboratory enabling us to work with select attenuated agents
such as anthrax and botulinum toxins, tularemia, monkeypox and
other priority DOD agents and pathogens of global concern, and
increasing the Company’s vivarium footprint, allowing it to execute
and enhance data generation related to infectious disease
preclinical studies, in order to evaluate the efficacy,
immunogenicity, and safety of vaccines and therapeutics against
bacterial and viral pathogens. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the ability to work with select attenuated
agents such as anthrax and botulinum toxins, tularemia, monkeypox
and other priority DOD agents and pathogens of global concern at
the state-of-the-art BSL-2 laboratory and the Company’s ability to
execute and enhance data generation related to infectious disease
preclinical studies, in order to evaluate the efficacy,
immunogenicity, and safety of vaccines and therapeutics against
bacterial and viral pathogens, NightHawk’s ability to commence
operation in San Antonio and Kansas when anticipated and to
successfully operate as a CDMO, NightHawk’s and its subsidiaries’
ability to maintain license agreements, the continued maintenance
and growth of NightHawk’s and its subsidiaries’ patent estates,
NightHawk’s product candidates demonstrating safety and
effectiveness, as well as results that are consistent with prior
results, the ability to initiate clinical trials and if initiated,
the ability to complete them on time and achieve the desired
results and benefits continuing enrollment as expected, the ability
to obtain regulatory approval for commercialization of product
candidates or to comply with ongoing regulatory requirements,
regulatory limitations relating to NightHawk’s ability to promote
or commercialize its product candidates for the specific
indications, acceptance of product candidates in the marketplace
and the successful development, marketing or sale of NightHawk’s
products, developments by competitors that render such products
obsolete or non-competitive, and other factors described in
NightHawk’s annual report on Form 10-K for the year ended December
31, 2021, subsequent quarterly reports on Form 10-Qs and any other
filings NightHawk makes with the SEC. The information in this
presentation is provided only as of the date presented, and
NightHawk undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@heatbio.com
Nighthawk Biosciences (AMEX:NHWK)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Nighthawk Biosciences (AMEX:NHWK)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024